Evidence map›Paper›PMID 41993692›Full record

ArticleiScience2026

LINC01929 mediates breast cancer immunosuppression and is an immunotherapy target.

Jaganathan Venkatesh, Marie-Claire D Wasson, Raj Pranap Arun, Hannah F Cahill, Olivia L Walker, Cheryl A Dean, Wasundara Fernando, Maya R MacLean, Meghan E McLean, Bakhmala Khan and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Jaganathan VenkateshDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Marie-Claire D WassonDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Raj Pranap ArunDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Hannah F CahillDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Olivia L WalkerDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Cheryl A DeanDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Wasundara FernandoDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Maya R MacLeanDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Meghan E McLeanDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Bakhmala KhanDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Perryn S KruthDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Mukhayyo SultonovaBeatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
Sarah NersesianBeatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
Stacey N LeeBeatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
Modeline N LongjohnBeatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
Christopher S HughesBiological Mass Spectrometry Core Facility, Dalhousie University, Halifax, NS, Canada.
Thomas J BelbinDivision of Biomedical Sciences, Memorial University of Newfoundland, St. John's, NL, Canada.
Daniel GastonDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Joao A PauloDepartment of Cell Biology, Harvard Medical School, Boston, MA, USA.
Gregory C KnappNova Scotia Health Authority, Halifax, NS, Canada.
Gillian BethuneDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Shashi GujarDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
Jeanette E BoudreauDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.
J Patrick MurphyBeatrice Hunter Cancer Research Institute, Halifax, NS, Canada.
Paola MarcatoDepartment of Pathology, Dalhousie University, Halifax, NS, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To identify long non-coding RNAs (lncRNAs) involved in breast cancer immunosuppression, we analyzed lncRNA expression and their correlation with tumor-infiltrating lymphocytes, association with worse patient outcomes, and enrichment in breast cancer and identified LINC01929 was a top hit in breast and other cancer types. Knockdown of LINC01929 in breast cancer cell lines reduced cell survival, cell cycle progression, inhibited tumor growth, and altered the expression of genes involved in growth, immune, and antigen presentation pathways. LINC01929 acts as a competitive endogenous RNA, regulating a cancer-promoting and immunosuppressive microRNA-mRNA network. Targeting LINC01929 in breast cancer cells increases proteasomal activity, and cell surface levels of human leukocyte antigen calls I (HLA I) and programmed death-ligand 1 (PD-L1). In breast tumors, LINC01929 expression negatively correlated with T cell abundance. Targeting LINC01929 sensitized breast cancer cells to activated T cell killing. These findings identify LINC01929 as an immunotherapy target to overturn breast cancer immunosuppression.

Indexed as

immunologymolecular biologyoncology

Identifiers

PMID41993692
PMCPMC13081058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.